| 摘要 |
The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.; |
| 主权项 |
1. A compound of Formula (I): wherein:
the dashed lines are independently an optional bond;Z1, Z2, and Z3 are —N— or CH, provided that at least one and not more than two of Z1, Z2, and Z3 are simultaneously N;L is O, CO, CH2, S, SO, SO2, NR, NRCO, CONR, NR′SO2, SO2NR′, or NRCONR′, where each R and R′ is independently hydrogen, alkyl, or cycloalkyl;Ar is aryl, heteroaryl, cycloalkyl or heterocyclyl;one of R1 and R5 is hydrogen, alkyl, hydroxy, cyano, alkoxy, halo, haloalkyl, or haloalkoxy and the other of R1 and R5 is:
formula (a) or (b); where P is a bond, NRa (where Ra is hydrogen or alkyl), —O—, S, SO, SO2, alkylene or heteroalkylene;Q is a bond, aryl or heteroaryl wherein aryl or heteroaryl is optionally substituted with one or two substituents independently selected from hydrogen, halo, alkyl, alkoxy, alkylhio, haloalkyl, or haloalkoxy;Xa is O, S, N(H), or N(alkyl);Rc′ is hydrogen, alkyl, substituted alkyl, haloalkoxy, cycloalkyl, or cycloalkyleneNRdRe where Rd and Re are independently hydrogen, alkyl, or cycloalkyl;R2 is hydrogen, alkyl, hydroxy, alkoxy, cyano, halo or haloalkyl;R3 and R4 are independently hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl or haloalkoxy; andR6 and R7 are independently hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, carboxy, alkoxycarbonyl, cyano, —CONH2, amino, monosubstituted or disubstituted amino; or a pharmaceutically acceptable salt thereof. |
